KEY POINTS
- Eli Lilly did not say what symptoms the ill patient developed
- President Trump was given an antibody cocktail as part of his COVID treatment
- AstraZeneca earlier paused it’s vaccine trial but has since restarted it in the U.K.
Eli Lilly (LLY) on Tuesday paused its coronavirus antibody trial because of a potential safety concern just one day after Johnson & Johnson (JNJ) paused its COVID-19 vaccine trial because of an unexplained illness.
The New York Times reported emails between Lilly and federal government officials concerned the trial testing the benefits of the antibody therapy on hundreds of hospitalized COVID-19 patients. All study patients also were receiving Gilead’s (GILD) trial remedy Remdesivir.
The Times said no details were provided on the number of volunteers who fell ill or any details about their illnesses.
Last week, Lilly reported just two test subjects had serious infusion reactions.
President Donald Trump received